Ayala Pharmaceuticals (NASDAQ:ADXS) coverage was initiated by analysts at StockNews.com

Stock analysts at StockNews.com have initiated coverage on the stock Ayala Pharmaceuticals (NASDAQ:ADXS – Get a Free Report) in a research report issued to clients and investors on Friday. The brokerage has set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of Ayala Pharmaceuticals opened at $0.02 on Friday. The company has a 50-day moving average of $0.10 and a 200-day moving average of $0.39. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $1.49. The stock has a market cap of $852,660.00, a PE ratio of 0.00 and a beta of 1.56.

About Ayala Pharmaceuticals

(Get a free report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, is primarily focused on developing and commercializing small molecule therapies for people living with rare tumors and aggressive cancers. The company’s lead candidates in development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacitarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in inadequate acute myeloid leukemia.

See Also

Receive daily news and reviews for Ayala Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com ‘s FREE daily email newsletter.